JP2007520486A - N−デアセチルチオコルヒチン誘導体、その使用およびそれを含有する医薬製剤 - Google Patents
N−デアセチルチオコルヒチン誘導体、その使用およびそれを含有する医薬製剤 Download PDFInfo
- Publication number
- JP2007520486A JP2007520486A JP2006550141A JP2006550141A JP2007520486A JP 2007520486 A JP2007520486 A JP 2007520486A JP 2006550141 A JP2006550141 A JP 2006550141A JP 2006550141 A JP2006550141 A JP 2006550141A JP 2007520486 A JP2007520486 A JP 2007520486A
- Authority
- JP
- Japan
- Prior art keywords
- linker
- deacetylthiocolchicine
- compounds
- formula
- meo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NUNCOHUMTCDISK-AWEZNQCLSA-N (7s)-7-amino-1,2,3-trimethoxy-10-methylsulfanyl-6,7-dihydro-5h-benzo[a]heptalen-9-one Chemical class C1([C@@H](N)CC2)=CC(=O)C(SC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC NUNCOHUMTCDISK-AWEZNQCLSA-N 0.000 title abstract description 20
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 125000005647 linker group Chemical group 0.000 claims abstract description 14
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 5
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
- 239000001257 hydrogen Substances 0.000 claims abstract description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000004955 1,4-cyclohexylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:1])C([H])([H])C([H])([H])C1([H])[*:2] 0.000 claims description 2
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 5
- 230000002456 anti-arthritic effect Effects 0.000 abstract description 3
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- CMEGANPVAXDBPL-INIZCTEOSA-N n-[(7s)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(SC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC CMEGANPVAXDBPL-INIZCTEOSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 229960001338 colchicine Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 3
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- -1 3-O-demethylthiocolchicine glucoside Chemical class 0.000 description 2
- IBOFVQJTBBUKMU-UHFFFAOYSA-N 4,4'-methylene-bis-(2-chloroaniline) Chemical compound C1=C(Cl)C(N)=CC=C1CC1=CC=C(N)C(Cl)=C1 IBOFVQJTBBUKMU-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- MPFLRYZEEAQMLQ-UHFFFAOYSA-N dinicotinic acid Chemical compound OC(=O)C1=CN=CC(C(O)=O)=C1 MPFLRYZEEAQMLQ-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- FTQWRYSLUYAIRQ-UHFFFAOYSA-N n-[(octadecanoylamino)methyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCNC(=O)CCCCCCCCCCCCCCCCC FTQWRYSLUYAIRQ-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- VGHSXKTVMPXHNG-UHFFFAOYSA-N 1,3-diisocyanatobenzene Chemical compound O=C=NC1=CC=CC(N=C=O)=C1 VGHSXKTVMPXHNG-UHFFFAOYSA-N 0.000 description 1
- PXGZQGDTEZPERC-UHFFFAOYSA-N 1,4-cyclohexanedicarboxylic acid Chemical compound OC(=O)C1CCC(C(O)=O)CC1 PXGZQGDTEZPERC-UHFFFAOYSA-N 0.000 description 1
- ALQLPWJFHRMHIU-UHFFFAOYSA-N 1,4-diisocyanatobenzene Chemical compound O=C=NC1=CC=C(N=C=O)C=C1 ALQLPWJFHRMHIU-UHFFFAOYSA-N 0.000 description 1
- OVBFMUAFNIIQAL-UHFFFAOYSA-N 1,4-diisocyanatobutane Chemical compound O=C=NCCCCN=C=O OVBFMUAFNIIQAL-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- KQQJCMQYSFBHHO-UHFFFAOYSA-N 3-(dimethoxymethyl)benzaldehyde Chemical compound COC(OC)C1=CC=CC(C=O)=C1 KQQJCMQYSFBHHO-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- PPYGHEFPVPYFDC-UHFFFAOYSA-N NC(N)=O.NC(N)=O.NC1=CC=CC(N)=C1 Chemical compound NC(N)=O.NC(N)=O.NC1=CC=CC(N)=C1 PPYGHEFPVPYFDC-UHFFFAOYSA-N 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008431 aliphatic amides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000011024 colonic benign neoplasm Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- JEHCHYAKAXDFKV-UHFFFAOYSA-J lead tetraacetate Chemical compound CC(=O)O[Pb](OC(C)=O)(OC(C)=O)OC(C)=O JEHCHYAKAXDFKV-UHFFFAOYSA-J 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/30—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/41—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/43—Y being a hetero atom
- C07C323/44—X or Y being nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
- C07C2603/34—Benzoheptalenes; Hydrogenated benzoheptalenes
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Description
コルヒチンおよびチオコルヒチンは、以前から医学的慣行で知られている。コルヒチンは、痛風および関連する炎症状態の療法に使用される。3−O−デメチルチオコルヒチングルコシドは、痙縮および拘縮による筋肉痛の筋弛緩薬(miorelaxant)として使用される。しかし、両者の場合、これらの化合物の使用はその高い毒性のために制限される。
本発明は、式IのN−デアセチルチオコルヒチン誘導体
リンカーは、二価の直鎖または分枝のC1〜C8アルキル残基、C3〜C8シクロアルキル、フェニレンまたはC4〜C6複素環であり、
G1およびG2結合部は、同じか異なっていてもよく、−CO−、−CONH−、R2が水素または直鎖C1〜C4アルキル残基である−CR2−基であるか、あるいはG1−リンカー−G2基は−CO−基である]に関する。
発明の開示
今回、式Iの化合物は、特に、MDR(多剤耐性)表現型を発現する細胞に対して、コルヒチンおよびチオコルヒチンより高い抗増殖活性を有することを見出した。
発明の詳細な開示
次式のN−デアセチルチオコルヒチン誘導体
リンカーは、二価の直鎖または分枝のC1〜C8アルキル残基、C3〜C8シクロアルキル、フェニレンまたはC4〜C6複素環であり、
G1およびG2結合部は、同じか異なってもよく、−CO−、−CONH−、R2が水素または直鎖C1〜C4アルキル残基である−CR2−基であるか、あるいはG1−リンカー−G2基は−CO−基であり、
ただし、G1およびG2が共にCOの場合、またはG1が−CONH−であり、かつG2が−CO−の場合は、リンカーはアルキル残基とは異なる]が開示される。
表1
実施例1 − 3,5−ピリジンジカルボン酸ビス−(N−デアセチルチオコルヒチン)アミド
10gのN−デアセチルチオコルヒチンを60mlの塩化メチレンに溶解する。次いで、2.24g(0.5当量)の3,5−ピリジンカルボン酸、1.64g(0.5当量)のN,N−ジメチルアミノピリジン(DMAP)および8.3g(1.5当量)のジシクロヘキシルカルボジイミド(DCC)を、激しい攪拌下で添加する。この混合物を、TLC(AcOEt:MeOH 10:1)により反応を監視しながら、試薬が見えなくなるまで攪拌したままにする(約12時間)。次いで、この溶液をセライトを通してろ過し、パッドを塩化メチレン(2×100ml)で洗浄する。組み合わせた有機相を、先ず同体積の1N HClで、次いでIN NaOHで洗浄する。この有機相を硫酸ナトリウムにより乾燥し、真空下で蒸発させる。この残渣を、シリカゲル(AcOEt:MeOH 10:1)によるろ過により精製する。得られた生成物を真空下40℃で静止乾燥機中で一晩乾燥して、7.5gの最終生成物を得る。
13CNMR(75MHz,CDCl3):182.64、164.25、158.88、154.12、152.59、152.34、151.33、141.92、139.33、135.48、134.47、132.74、129.04、128.54、127.48、125.71、107.74、61.88、61.61、56.49、53.03、30.09、15.41。
10gのN−デアセチルチオコルヒチンを60mlの塩化メチレンに溶解する。次いで、2.31g(0.5当量)のトランス−1,4−シクロヘキサンジカルボン酸、1.64g(0.5当量)のDMAPおよび8.3g(1.5当量)のDCCを、激しい攪拌下で添加する。この混合物を12時間攪拌したままにし、TLC(AcOEt:MeOH 10:1)により監視し、次いで、セライトを通してろ過し、パッドを塩化メチレン(2×20ml)で洗浄する。組み合わせた有機相を、同体積の1N HCl、IN NaOHおよびブラインで洗浄し、Na2SO4により乾燥する。溶媒を減圧下で蒸発させた後、この残渣を直接カラムクロマトグラフィー(AcOEt:MeOH 12:1)により精製する。この生成物をメタノール(10体積/体積)から結晶化し、真空下40℃で静止乾燥機中で一晩乾燥して、6.6gの純粋な化合物を得る。
5gのイソフタル酸から出発して実施例1の手順に追従して、この生成物を結晶性固体として得る(収率:82%)。
2.0gのN−デアセチルチオコルヒチンを150mlの無水テトラヒドロフランに溶解する。次いで、0.5当量の1,4−フェニレンジイソシアネート(0.4g)を添加する。この反応混合物を、TLC(DCM−EtOH 95:5、Rf=0.30)により監視しながら、室温で2日間攪拌したままにする。溶媒を蒸発除去し、この粗製物を酢酸エチルから再結晶させて、0.95gの純粋な生成物を得る(38%)。
2.0gのN−デアセチルチオコルヒチンおよび0.4gの1,3−フェニレンジイソシアネートから出発して実施例IVの手順に追従して、所望の生成物を得る(収率:42%)。
2.0gのN−デアセチルチオコルヒチンおよび0.4gの1,4−ブタンジイソシアネートから出発して実施例IVの手順に追従して、所望の生成物を得る(収率:63%、0.4g)。TLC(DCM−EtOH=95:5)Rf=0.38。
2.0gのN−デアセチルチオコルヒチンを100mlのクロロホルムに溶解する。0.5当量のイソフタルアルデヒドジメチルアセタールおよび0.01%のピリジニウムトシレートを添加する。この混合物を、一晩還流し、室温に冷却させておき、氷浴中に置く。8当量のトリアセトキシ水素化ホウ素ナトリウムを添加し、この混合物を1日間攪拌したままにする。次いで、この溶液をろ過し、同体積の0.1N HCLおよび次いで飽和炭酸水素ナトリウム水溶液で洗浄する。この有機相を硫酸ナトリウムにより乾燥し、溶媒を蒸発除去する。この粗製物をフラッシュクロマトグラフィーにより精製して、0.49gの生成物を得る。
1gの3,5−ピリジンジカルボン酸ビス−(N−デアセチルチオコルヒチン)アミドを20mlのジオキサンに溶解する。得られた溶液をアルブミンの5%生理的溶液中に徐々に滴下して、均一な乳状懸濁液を得る。この混合物を、2時間無菌の条件で攪拌したままにし、次いで凍結乾燥する。
Claims (9)
- G1およびG2が共にCOまたはCONHである、請求項1に記載の化合物。
- リンカーが、フェニレン、C5〜C6シクロアルキレンまたは複素環基である、請求項1または2に記載の化合物。
- リンカーが、2〜6個の炭素原子を有する二価の直鎖アルキル残基から選択される、請求項1または2に記載の化合物。
- リンカーが、1,3−シクロヘキシレンおよび1,4−シクロヘキシレンから選択される、請求項1または2に記載の化合物。
- リンカーが、1,2−、1,3−または1,4−フェニレンから選択される、請求項1または2に記載の化合物。
- リンカーが、3,5または2,5または2,6位でG1およびG2基に結合されたピリジル、ピペリジニル、ピペラジニルから選択される、請求項1または2に記載の化合物。
- 抗腫瘍、抗関節炎、抗炎症および抗ウイルスに使用するための式Iの化合物。
- 活性成分として式Iの化合物を含有し、適当な担体および/または賦形剤を混合する薬剤組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000164A ITMI20040164A1 (it) | 2004-02-03 | 2004-02-03 | Derivati di n.deacetiltiocolchicina loro uso e formulazioni farmaceutiche che li contengono |
ITMI2004A000164 | 2004-02-03 | ||
PCT/EP2005/000987 WO2005075418A2 (en) | 2004-02-03 | 2005-02-01 | N-deacetylthiocolchicine derivatives, their use and pharmaceutical formulations containing them |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007520486A true JP2007520486A (ja) | 2007-07-26 |
JP4884983B2 JP4884983B2 (ja) | 2012-02-29 |
Family
ID=34835575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006550141A Active JP4884983B2 (ja) | 2004-02-03 | 2005-02-01 | N−デアセチルチオコルヒチン誘導体、その使用およびそれを含有する医薬製剤 |
Country Status (20)
Country | Link |
---|---|
US (4) | US7399788B2 (ja) |
EP (1) | EP1711461B1 (ja) |
JP (1) | JP4884983B2 (ja) |
KR (1) | KR101163794B1 (ja) |
CN (1) | CN100558705C (ja) |
AT (1) | ATE456554T1 (ja) |
AU (1) | AU2005211501B2 (ja) |
CA (1) | CA2555058C (ja) |
DE (1) | DE602005019135D1 (ja) |
DK (1) | DK1711461T3 (ja) |
ES (1) | ES2336010T3 (ja) |
HK (1) | HK1100877A1 (ja) |
IL (1) | IL177196A (ja) |
IT (1) | ITMI20040164A1 (ja) |
NO (1) | NO337208B1 (ja) |
PL (1) | PL1711461T3 (ja) |
PT (1) | PT1711461E (ja) |
RU (1) | RU2370486C2 (ja) |
SI (1) | SI1711461T1 (ja) |
WO (1) | WO2005075418A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012531407A (ja) * | 2009-07-08 | 2012-12-10 | ジェ イル ファーマシューティカル カンパニー リミテッド | トリサイクリック誘導体の製造方法 |
US11814360B2 (en) | 2017-10-05 | 2023-11-14 | Novomer, Inc. | Isocyanates, derivatives, and processes for producing the same |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006214100B2 (en) * | 2005-02-18 | 2012-05-31 | Abraxis Bioscience, Llc | Drugs with improved hydrophobicity for incorporation in medical devices |
JP2010502603A (ja) * | 2006-08-31 | 2010-01-28 | アブラクシス バイオサイエンス, エルエルシー | 血管形成を阻害し、血管形成関連疾患を処置する方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000503669A (ja) * | 1996-06-07 | 2000-03-28 | インデナ・ソシエタ・ペル・アチオニ | コルヒチン骨格化合物、それらの医薬としての用途、及びそれらを含有する組成物 |
WO2001068597A1 (en) * | 2000-03-17 | 2001-09-20 | Indena S.P.A. | N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them |
JP2007503459A (ja) * | 2003-04-14 | 2007-02-22 | カリフォルニア パシフィック メディカル センター | コルヒチン誘導体 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1344157A (fr) * | 1959-05-22 | 1963-11-29 | Roussel Uclaf | Nouvelles colchicines et leur procédé d'obtention |
-
2004
- 2004-02-03 IT IT000164A patent/ITMI20040164A1/it unknown
-
2005
- 2005-02-01 JP JP2006550141A patent/JP4884983B2/ja active Active
- 2005-02-01 AU AU2005211501A patent/AU2005211501B2/en not_active Ceased
- 2005-02-01 CA CA2555058A patent/CA2555058C/en active Active
- 2005-02-01 ES ES05707124T patent/ES2336010T3/es active Active
- 2005-02-01 KR KR1020067015170A patent/KR101163794B1/ko active IP Right Grant
- 2005-02-01 PL PL05707124T patent/PL1711461T3/pl unknown
- 2005-02-01 WO PCT/EP2005/000987 patent/WO2005075418A2/en active Application Filing
- 2005-02-01 SI SI200530939T patent/SI1711461T1/sl unknown
- 2005-02-01 CN CNB200580003821XA patent/CN100558705C/zh not_active Expired - Fee Related
- 2005-02-01 AT AT05707124T patent/ATE456554T1/de active
- 2005-02-01 DE DE602005019135T patent/DE602005019135D1/de active Active
- 2005-02-01 EP EP05707124A patent/EP1711461B1/en active Active
- 2005-02-01 RU RU2006127967/04A patent/RU2370486C2/ru active
- 2005-02-01 US US10/588,012 patent/US7399788B2/en active Active
- 2005-02-01 DK DK05707124.3T patent/DK1711461T3/da active
- 2005-02-01 PT PT05707124T patent/PT1711461E/pt unknown
-
2006
- 2006-08-01 NO NO20063509A patent/NO337208B1/no not_active IP Right Cessation
- 2006-08-01 IL IL177196A patent/IL177196A/en active IP Right Grant
-
2007
- 2007-08-08 HK HK07108622.2A patent/HK1100877A1/xx not_active IP Right Cessation
-
2008
- 2008-06-19 US US12/142,522 patent/US7687545B2/en active Active
- 2008-06-19 US US12/142,485 patent/US7579364B2/en active Active
- 2008-06-19 US US12/142,502 patent/US7582639B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000503669A (ja) * | 1996-06-07 | 2000-03-28 | インデナ・ソシエタ・ペル・アチオニ | コルヒチン骨格化合物、それらの医薬としての用途、及びそれらを含有する組成物 |
WO2001068597A1 (en) * | 2000-03-17 | 2001-09-20 | Indena S.P.A. | N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them |
JP2007503459A (ja) * | 2003-04-14 | 2007-02-22 | カリフォルニア パシフィック メディカル センター | コルヒチン誘導体 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012531407A (ja) * | 2009-07-08 | 2012-12-10 | ジェ イル ファーマシューティカル カンパニー リミテッド | トリサイクリック誘導体の製造方法 |
US11814360B2 (en) | 2017-10-05 | 2023-11-14 | Novomer, Inc. | Isocyanates, derivatives, and processes for producing the same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL196809B1 (pl) | Półsyntetyczne ekteinascydyny, kompozycje farmaceutyczne oraz zastosowanie półsyntetycznych ekteinascydyn | |
JP4884983B2 (ja) | N−デアセチルチオコルヒチン誘導体、その使用およびそれを含有する医薬製剤 | |
CN104125962A (zh) | 四环蒽醌衍生物 | |
EP1263719B1 (en) | N-deacetylthiocolchine derivatives and pharmaceutical compositions containing them | |
SK266991A3 (en) | 2-hydroxyethylaminosubstituted derivatives of 5,11-dioxo-5,6- -dihydro-11h-indeno£1,2-c|isoquinoline, a process for manufacture thereof and pharmaceutical composition containing the same | |
JPH075608B2 (ja) | ビンブラスチン誘導体 | |
JP2002507196A (ja) | 細胞増殖抑制剤としてのシアノグアニジン | |
AU2001248341A1 (en) | N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them | |
JPH08151379A (ja) | ビス(ピロロインドール)誘導体及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100915 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101215 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110114 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110518 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110909 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111108 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111207 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141216 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4884983 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |